1. Home
  2. AGEN vs AMRN Comparison

AGEN vs AMRN Comparison

Compare AGEN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.85

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Logo Amarin Corporation plc

AMRN

Amarin Corporation plc

HOLD

Current Price

$13.63

Market Cap

287.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
AMRN
Founded
1994
1989
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
274.8M
287.9M
IPO Year
1999
1998

Fundamental Metrics

Financial Performance
Metric
AGEN
AMRN
Price
$7.85
$13.63
Analyst Decision
Buy
Strong Sell
Analyst Count
2
1
Target Price
$14.50
$12.00
AVG Volume (30 Days)
873.0K
76.1K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
55.00
EPS
0.96
N/A
Revenue
$42,877,086.00
$181,104,000.00
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
$1.26
P/E Ratio
$7.52
N/A
Revenue Growth
89.95
39.22
52 Week Low
$2.71
$12.96
52 Week High
$8.85
$20.90

Technical Indicators

Market Signals
Indicator
AGEN
AMRN
Relative Strength Index (RSI) 54.50 42.10
Support Level $2.97 $13.48
Resistance Level $8.64 $14.50
Average True Range (ATR) 0.43 0.40
MACD -0.10 -0.01
Stochastic Oscillator 54.07 37.76

Price Performance

Historical Comparison
AGEN
AMRN

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About AMRN Amarin Corporation plc

Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

Share on Social Networks: